Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAV132 Dose Regimens with Moxifloxacin in Healthy Volunteers
NCT02917200Phase 1Completed
- Sponsor
- Da Volterra
- Start
- May 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DAV132 in Clostridioides difficile infection (CDI) and dysbiosis (12 arms), sponsored by Da Volterra. Primary endpoint: Area under the curve of free moxifloxacin fecal concentrations from D1 to D16. Started May 2016; status: completed.
02
Drugs
DAV132
03
Conditions
Clostridioides difficile infection (CDI)dysbiosis
Beyond the preview
Go deeper on NCT02917200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02917200.